Ataxion Secures $17,000,000 Series A Funding Round

  • Feed Type
  • Date
    3/19/2014
  • Company Name
    Ataxion
  • Mailing Address
    25 First Street Cambridge, MA 02141 USA
  • Company Description
    Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $17,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    In addition to participating in the Series A investment, Biogen Idec is providing non-dilutive R&D and other funding to Ataxion. Biogen Idec will have the option to acquire Ataxion to continue development of the program upon completion of the Phase 1 multiple ascending dose (MAD) study at pre-negotiated terms, including upfront and milestone payments.
  • M&A Terms
  • Venture Investor
    Atlas Venture
  • Venture Investor
    Biogen Idec

By posting a comment, you agree to our terms and conditions.